The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Genentech
Stock and Other Ownership Interests - Genentech
MORPHEUS-EC: A phase Ib/II open-label, randomized study of first-line tiragolumab (tira) + atezolizumab (atezo) + chemotherapy (CT) in patients (pts) with esophageal cancer (EC).
 
Jong-Mu Sun
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
Sung-Bae Kim
Stock and Other Ownership Interests - Genopeaks
Honoraria - DAEHWA Pharmaceutical; Kalbe Farma; LegoChem Biosciences
Consulting or Advisory Role - AstraZeneca; BeiGene; DAEHWA Pharmaceutical; Daiichi Sankyo/Astra Zeneca; ISU Abxis; Lilly (Inst); OBI Pharma
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Andrew Strickland
No Relationships to Disclose
 
Zev A. Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Lilly; Merck; Merck KGaA; Novartis; Pfizer; PureTech; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck
 
Ian Chau
Honoraria - Bristol-Myers Squibb; Eisai; Lilly; Novartis; Roche/Genentech; SERVIER
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; OncXerna Therapeutics; Roche/Genentech; Seagen; SERVIER; Sotio; Taiho Oncology; Turning Point Therapeutics
Research Funding - Janssen-Cilag (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - BMS; SERVIER
 
Sharon Pelles-Avraham
No Relationships to Disclose
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; Amgen; Arcus Biosciences; Astellas Pharma; BeiGene; BeiGene; Bristol-Myers Squibb; Geneos; Gilead Sciences; Insys Therapeutics; Merck; Novartis; SERVIER; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Ritu Malhotra
No Relationships to Disclose
 
Qingyuan Liu
Employment - Roche
 
Sijing Li
Employment - F. Hoffmann LaRoche
 
Edward Cha
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
 
Swapna Rahalkar
Employment - Glenmark
 
Simon Allen
No Relationships to Disclose
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; MSD; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo